138 related articles for article (PubMed ID: 34325988)
1. The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer.
Wenzel M; Dariane C; Saad F; Karakiewicz PI; Mandel P; Chun FKH; Tilki D; Graefen M; Delouya G; Taussky D; Würnschimmel C
Urol Oncol; 2022 Feb; 40(2):57.e15-57.e23. PubMed ID: 34325988
[TBL] [Abstract][Full Text] [Related]
2. Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-Significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control.
Schroeder C; Geiger F; Siebert FA; Baumann R; Bockelmann G; Schultze J; Kimmig B; Dunst J; Galalae R
Brachytherapy; 2019; 18(1):8-12. PubMed ID: 30482622
[TBL] [Abstract][Full Text] [Related]
3. Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.
Boehm K; Schiffmann J; Tian Z; Lesmana H; Larcher A; Mandel P; Karakiewicz PI; Graefen M; Schwarz R; Krüll A; Tilki D
Urol Oncol; 2016 Mar; 34(3):119.e11-8. PubMed ID: 26602027
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for biochemical recurrence after a tissue-ablative prostate-specific antigen <0.2 ng/mL.
Taussky D; Lambert C; Meissner N; Bahary JP; Delouya G
Brachytherapy; 2018; 17(5):794-798. PubMed ID: 30153914
[TBL] [Abstract][Full Text] [Related]
5. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.
Skove SL; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Moreira DM; Freedland SJ
Urology; 2017 Oct; 108():129-134. PubMed ID: 28735016
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA(TM) , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study.
Lepor H; Cheli CD; Thiel RP; Taneja SS; Laze J; Chan DW; Sokoll LJ; Mangold L; Partin AW
BJU Int; 2012 Jun; 109(12):1770-5. PubMed ID: 21992499
[TBL] [Abstract][Full Text] [Related]
7. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
8. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.
Pei X; Wu K; Sun Y; Gao X; Gou X; Xu J; Gao F; He D; Li L;
Urol Oncol; 2020 Jan; 38(1):2.e11-2.e17. PubMed ID: 31672485
[TBL] [Abstract][Full Text] [Related]
9. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
10. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
Lee WR; Hanlon AL; Hanks GE
J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence.
Inoue H; Nishimura K; Yamaguchi S; Nonomura N; Hara T
Int J Clin Oncol; 2015 Feb; 20(1):171-5. PubMed ID: 24652165
[TBL] [Abstract][Full Text] [Related]
12. Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival.
Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
Radiat Oncol; 2017 Jun; 12(1):98. PubMed ID: 28615058
[TBL] [Abstract][Full Text] [Related]
13. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782
[TBL] [Abstract][Full Text] [Related]
14. Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer.
Bartkowiak D; Thamm R; Siegmann A; Böhmer D; Budach V; Wiegel T
Radiother Oncol; 2021 Jan; 154():255-259. PubMed ID: 32920006
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
16. Biochemical recurrence after radical prostatectomy according to nadir prostate specific antigen value.
Chung JH; Jeong JY; Lee JY; Song W; Kang M; Sung HH; Jeon HG; Jeong BC; Seo SI; Lee HM; Jeon SS
PLoS One; 2021; 16(5):e0249709. PubMed ID: 33939714
[TBL] [Abstract][Full Text] [Related]
17. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies.
Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411
[TBL] [Abstract][Full Text] [Related]
18. Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint.
Perez CA; Michalski JM; Lockett MA
Int J Radiat Oncol Biol Phys; 2001 Apr; 49(5):1287-96. PubMed ID: 11286836
[TBL] [Abstract][Full Text] [Related]
19. Body mass index is not a prognostic marker for prostate-specific antigen failure and survival in Dutch men treated with brachytherapy.
van Roermund JG; Hinnen KA; Battermann JJ; Witjes JA; Bosch JL; Kiemeney LA; van Vulpen M
BJU Int; 2010 Jan; 105(1):42-8. PubMed ID: 19519759
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer.
Critz FA; Levinson AK; Williams WH; Holladay DA
J Clin Oncol; 1996 Nov; 14(11):2893-900. PubMed ID: 8918485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
